| |
Wednesday, January 11, 2023 | 2:00pm ET Recent advances in natural language processing (NLP) caused an explosion of practical use cases that have now become viable. This webinar for healthcare & life sciences leaders surveys common NLP applications that are being widely deployed, including real world data extraction from pathology & radiology reports, patient risk adjustment & HCC coding, and more. Register now.
|
|
Today's Big NewsJan 4, 2023 |
|
Tuesday, January 24, 2023 | 11am ET / 8am PT UGTs are the most common enzymes involved in metabolism after CYP enzymes, followed by numerous hydrolases, carbonyl reductases, aldehyde oxidase and other enzymes. Hear Dr. Brian Ogilvie discuss case studies and strategies to address non-CYP related metabolism questions in your drug’s safety assessment. Register now.
|
|
| By Fraiser Kansteiner As many in the U.S. struggle with rising costs of living, large pharmaceutical companies have opted to ring in the New Year with price hikes. |
|
|
|
By Max Bayer Moderna CEO Stéphane Bancel says data from the company's preclinical monkeypox, or mpox, vaccine are "fantastic," but don't expect to see it on the market any time soon, if at all. |
By Heather Landi Oregon’s health agency approved Amazon’s proposed deal to buy One Medical, moving the tech giant one step closer to sealing the $3.9 billion acquisition. |
By Andrea Park Fresh out of the 130-year-old nest, GE HealthCare is ready to move fast and break things. |
|
Tuesday, January 24, 2023 | 11am ET / 8am PT Your CRO is a finalist in a project bid and clinical supplies are one of the aspects that you will manage on behalf of the client via a partner. Register now.
|
|
By Ben Adams Bausch + Lomb has joined forces with the nonprofit Glaucoma Research Foundation for the U.S. launch of a new eye health campaign “Screen, Protect, Cure.” |
By Annalee Armstrong,Gabrielle Masson,Max Bayer Layoffs hit biotech fast and furious in 2022. The Fierce Biotech Layoff Tracker lists the reported events from January to December. |
By Andrea Park Two years after submitting one of its mouthpieces for an FDA clearance that would allow it to be used to treat obstructive sleep apnea—a submission that was initially met with rejection from the agency—Vivos Therapeutics has emerged victorious. |
By Robert King Drugmakers complain they need more guidance from CMS on calculating best prices for Medicare Part B reimbursement, a new OIG analysis finds. |
By Angus Liu In a closely watched patent dispute playing out at the U.S. Supreme Court, Amgen has drummed up support from fellow drugmakers large and small, as well as industry associations and intellectual property groups. |
By Conor Hale To those who've always wanted to digitally monitor their bathroom health at home: you're in luck. |
By Nick Paul Taylor Roivant Sciences has shown its hand in the red-hot race for a new ulcerative colitis market. Weeks after Prometheus Biosciences wowed investors, and with the ink on its deal with Pfizer to enter the race still drying, Roivant has shared phase 2b data that it claims position it as a best-in-class contender. |
By Frank Diamond Abortion pills will now be available at retail pharmacies, according to a change in regulations governing how the medications can be dispensed that the Food and Drug Administration finalized yesterday. |
By Zoey Becker Right before the New Year, Pfizer's Hospira and Accord were faced with drug recalls. The companies each pulled a lot of medicines for differing reasons. |
Fierce podcastsDon't miss an episode |
| | In this week's episode of "Podnosis," we talk about how telehealth exacerbates health inequities. We also discuss the impact of anti-trans legislation on healthcare and what providers can do to break down barriers to care for gender-diverse populations. |
|
|---|
|
|
|
Wednesday, January 25, 2023 | 1:00pm ET In this webinar, you’ll learn about a case study pursued in collaboration with Geneos Therapeutics and Personalis to utilize a tumor-informed ctDNA assay to retrospectively analyze clinical response to a class of personalized immunotherapies developed against tumor-specific neoantigens in advanced hepatocellular cancer (HCC) patients. Register now.
|
|
| WhitepaperThis paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
